Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges.
Therapeutic options in advanced stage hepatocellular carcinoma have been very poor until the discovery of new therapeutic agents that target the molecular pathways involved in hepatocarcinogenesis. In this paper we try to review the most important molecular agents in development, with a specific focus on sorafenib's role and safety profile, especially in the treatment of patients with suboptimal liver function.
Section of Gastroenterology, Department of Surgical, Oncological and Gastroenterological Sciences, Padua University, Italy.
Anna
A
Giacomin
Adriana
A
Sergio
Veronica
V
Vanin
Alessia
A
Gazzola
Nora
N
Cazzagon
Fabio
F
Farinati
D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000639:trends*; D011956:Receptors, Cell Surface / Q000378:metabolism; D015398:Signal Transduction
D036341:Intercellular Signaling Peptides and Proteins; D011956:Receptors, Cell Surface